Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Credo Technology Group Holding Ltd (CRDO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Credo Technology Group Holding Ltd — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Credo Technology Group Holding Ltd trades at $254.35 (market cap $45.95B). The key difference: Credo Technology Group Holding Ltd is far larger — about 10.2× ACADIA Pharmaceuticals Inc.'s market cap. Which is the better fit depends on your goals.
| ACAD | CRDO | |
|---|---|---|
Market Cap | $4.49B | $45.95B |
Sector | Health | Technology |
52-Week High | $28.06 | $302.52 |
52-Week Low | $20.06 | $87.81 |
Enterprise Value | $3.69B | $44.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
CRDO trades at $265.55, up 9.77% in 24 hours, with strong bullish momentum from moving averages and recent earnings beats. The stock shows robust fundamentals with 35.37% net income margin and 34.41% ROE, though valuations are elevated at P/E 105.8 and P/S 37.44. Recent news highlights AI-driven growth in connectivity solutions, with revenue surging 157% YoY in Q4 2026.
Outlook remains positive given analyst consensus of $273.33 price target and 86.7% buy ratings, but high valuations and competitive pressures pose risks. Continued execution on AI networking demand could drive further upside, while any slowdown in growth may trigger multiple compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →
